Table of Contents
<< Previous Issue | Jun 2017 (Vol: 2017, Issue: 6) | Next Issue >> |
- Section: Licensing
-
J & J Commits up to US$1 B for Protagonist’s Preclinical Crohn’s Disease Drug
-
Pfizer Bolsters Anti-Infectives Presence with Basilea Deal
- Section: Mergers & Acquisitions
-
Biogen Spin-Off Bioverativ to Acquire True North Therapeutics for up to US$825 M
- Section: Research & Development
-
Lilly Bolsters Diabetes Pipeline with KeyBioScience Collaboration